- Jandal Evaluationluchia's Dvc Site Website
- Jandal Evaluationluchia's Dvc Site Login
- Jandal Evaluationluchia's Dvc Site Sign In
- Jandal Evaluationluchia's Dvc Site Officiel
Welcome to the Cardiovascular Consultants of Southern Delaware. We are pleased you are visiting our practice through the website. Whether you are a patient or provider, we have designed our website to provide you with the critical information you need and in many cases obtain what you need directly from our site. Each of our sections allows you to interact with and learn about the unique features of Cardiovascular Consultants of Southern Delaware. Our practice is comprised of the finest Cardiologists, Physician Extenders and Cardiac Technologists in Southern Delaware.
Cardiovascular Consultants of Southern Delaware does not perform COVID-19 testing or provide the COVID-19 vaccine. Please contact your Primary Care Provider for further information.
In response to the Coronavirus pandemic, Cardiovascular Consultants of Southern Delaware has decided to implement the following measures to reduce the risk of exposure to patients, providers and staff:
We are routinely cleaning and sanitizing waiting rooms, exam rooms and frequently touched areas. We are also taking the proper precautions by wearing Personal Protective Equipment to help keep our patients and themselves safe.
靴 山陽 1day (2014/11/29) 小物入れ アクセサリーケース カルティエ 指輪. Pregnancy and the puerperium are well-established risk factors for deep vein thrombosis (DVT) and pulmonary embolism (PE), which are collectively referred to as venous thromboembolic disease (VTE).
We are offering tele-medicine visits for patients that either do not feel comfortable coming into the office, not well enough to come into the office or have been exposed or on quarantine due to the COVID-19 virus. Please advise a staff member if you would like to have a tele-medicine visit.
In order to limit the volume of individuals in our waiting areas, we are only allowing the patient in the building. Non- essential family members/caregiver should not enter the building with patients unless they are needed for direct care associated with the patient as determined on an individual basis by our Providers. If it is determined that the patient does require assistance during a visit, we are limiting that essential family member/caregiver to one person.
Once the patient has checked in, we ask that you wait in the vehicles vs our waiting room until an exam room becomes available.
If you do not have an appointment, we ask that you contact the office via telephone or by using the patient portal.
If you are currently scheduled for a routine visit and are not having any cardiac issues, you may be asked to delay your follow up. Saint seiya hades episode 1.
Jandal Evaluationluchia's Dvc Site Website
If you are experiencing any fever, cough, sore throat, runny nose or shortness of breath, please contact your Primary Care Physician for further guidance or go to a walk-in facility.
If you have any further questions, please give the office a call at (302) 645 1233.
Jandal Evaluationluchia's Dvc Site Login
- Kearon C, Akl EA, Omelas J, et al.
- Antithrombotic Therapy for VTE Disease: CHEST Guideline and Expert Panel Report. Chest 2016;149:315-352.
The following are 11 key points about this updated guideline document from the American College of Chest Physicians on antithrombotic therapy for venous thromboembolism (VTE):
- For VTE without an associated cancer diagnosis, all direct oral anticoagulants (dabigatran, rivaroxaban, apixaban, or edoxaban) are recommended over vitamin K antagonist (VKA) therapy (all Grade 2B) and VKA therapy is recommended over low molecular weight heparin (LMWH; Grade 2C).
- For VTE associated with cancer, LMWH is recommended over VKA (Grade 2B) or any direct oral anticoagulants (all Grade 2C).
- Anticoagulants should stop after 3 months of therapy in patients with an acute, proximal deep venous thrombosis (DVT) provoked by surgery rather than shorter or longer treatment courses (Grade 1B).
- Anticoagulants should also be stopped after 3 months in patients with a proximal DVT or pulmonary embolism (PE) provoked by a nonsurgical transient risk factor over shorter or longer courses (Grade 1B for high bleeding risk patients, Grade 2B for low or moderate bleeding risk patients).
- Anticoagulation should be given for 3 months in patients with a first unprovoked VTE and a high risk of bleeding (Grade 1B), but should be extended without a scheduled stop date in patients with a low or moderate risk of bleeding (Grade 2B).
- For patients with acute VTE who are treated with anticoagulation, the guideline recommends against the use of an inferior vena cava filter (Grade 1B).
- For patients with an unprovoked proximal DVT or PE who are stopping anticoagulant therapy, the guideline suggests the use of aspirin over no aspirin to prevent recurrent VTE if there are no contraindications to aspirin therapy (Grade 2B).
- For patients with acute DVT, the guideline recommends against the use of compression stockings routinely to prevent the post-thrombotic syndrome (Grade 2B).
- For patient with subsegmental PE and no DVT, the guideline suggests clinical surveillance over anticoagulation when the risk of VTE recurrence is low (Grade 2C). The guideline recommends the use of anticoagulation over surveillance when the risk of VTE recurrence is high (Grade 2C).
- For patients with an acute PE and hypotension (massive PE), the guideline recommends the use of thrombolytic therapy (Grade 2B), preferring systemic therapy over catheter-directed thrombolytic therapy (Grade 2C).
- For patients with recurrent VTE while treated with a non-LMWH anticoagulant, the guideline recommends changing to LMWH therapy (Grade 2C). If patients suffer a recurrent VTE while on LMWH treatment, the guideline recommends increasing the LMWH dose (Grade 2C).
Jandal Evaluationluchia's Dvc Site Sign In
Clinical Topics:Anticoagulation Management, Prevention, Pulmonary Hypertension and Venous Thromboembolism, Vascular Medicine, Anticoagulation Management and Venothromboembolism
Keywords:Anticoagulants, Antithrombins, Aspirin, Fibrinolytic Agents, Heparin, Low-Molecular-Weight, Hypotension, Primary Prevention, Pulmonary Embolism, Risk Factors, Thrombolytic Therapy, Vascular Diseases, Vena Cava Filters, Venous Thromboembolism, Venous Thrombosis, Vitamin K